{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:08:44Z","timestamp":1781852924464,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070609"],"award-info":[{"award-number":["32070609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270648"],"award-info":[{"award-number":["32270648"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91953120"],"award-info":[{"award-number":["91953120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018YFA0800302"],"award-info":[{"award-number":["2018YFA0800302"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012600","name":"ShanghaiTech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jbc.2023.103073","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T11:12:33Z","timestamp":1677496353000},"page":"103073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance"],"prefix":"10.1016","volume":"299","author":[{"given":"Liping","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meimei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Liang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2023.103073_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc.2016.83","article-title":"Maintaining cell identity: PRC2-mediated regulation of transcription and cancer","volume":"16","author":"Comet","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2023.103073_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg3607","article-title":"Chromatin modifiers and remodellers: regulators of cellular differentiation","volume":"15","author":"Chen","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jbc.2023.103073_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","article-title":"Targeting EZH2 in cancer therapy","volume":"29","author":"Yamagishi","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jbc.2023.103073_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbpa.2019.11.009","article-title":"Drugging histone methyltransferases in cancer","volume":"56","author":"Richart","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jbc.2023.103073_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jbc.2023.103073_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2023.103073_bib7","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2023.103073_bib8","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2023.103073_bib9","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2023.103073_bib10","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1158\/1535-7163.MCT-13-0876","article-title":"A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation","volume":"13","author":"Ott","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2023.103073_bib11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbc.2023.103073_bib12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbc.2023.103073_bib13","doi-asserted-by":"crossref","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2023.103073_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2023.103073_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2023.103073_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41419-022-04601-6","article-title":"Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer","volume":"13","author":"Chu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbc.2023.103073_bib17","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/j.annonc.2022.07.1376","article-title":"HJM-353: a potent, selective and orally bioavailable EED inhibitor with robust anti-tumor activities","volume":"33","author":"Ma","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2023.103073_bib18","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2021-151426","article-title":"Ftx-6058 induces fetal hemoglobin production and ameliorates disease pathology in sickle cell mice","volume":"138","author":"Matson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2023.103073_bib19","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2023.103073_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4383","article-title":"Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2","volume":"350","author":"Jiao","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jbc.2023.103073_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41594-018-0023-y","article-title":"Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes","volume":"25","author":"Poepsel","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbc.2023.103073_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.molcel.2018.03.020","article-title":"Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin","volume":"70","author":"Lee","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2023.103073_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2023.103073_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-019-0615-2","article-title":"Engaging chromatin: PRC2 structure meets function","volume":"122","author":"Chammas","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2023.103073_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2023.103073_bib26","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2023.103073_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12386","article-title":"Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16","volume":"105","author":"Ueda","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jbc.2023.103073_bib28","first-page":"3233","article-title":"Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in\u00a0vitro and in\u00a0vivo","volume":"15","author":"Lu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbc.2023.103073_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7785\/tcrt.2012.500315","volume":"12","author":"Zhong","year":"2013","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.jbc.2023.103073_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13148-021-01147-w","article-title":"PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis","volume":"13","author":"Zoroddu","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.jbc.2023.103073_bib31","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2023.103073_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2023.103073_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2020.12.008","article-title":"Targeting pan-essential genes in cancer: challenges and opportunities","volume":"39","author":"Chang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2023.103073_bib34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2023.103073_bib35","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2023.103073_bib36","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jbc.2023.103073_bib37","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2023.103073_bib38","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823002053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823002053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:36:44Z","timestamp":1762187804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925823002053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0021925823002053"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2023.103073","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2023.103073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"103073"}}